Earnings Call Summary | Burning Rock Biotech(BNR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Burning Rock Biotech(BNR.US) Q1 2024 Earnings Conference
The following is a summary of the Burning Rock Biotech Limited (BNR) Q1 2024 Earnings Call Transcript:
以下是Burning Rock Biotech Limited（BNR）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Burning Rock Biotech reported a 4% Q1 2024 revenue growth, predominantly driven by their in-hospital business.
The company recorded its lowest ever sales and marketing expenses as a portion of revenue at 35%.
The gross profit margin showed progress but no significant updates for this quarter.
Administrative expenses saw significant reduction compared to the previous year.
A significant reduction in expected cash outflows for 2024 was announced, promising a comfortable financial runway.
Burning Rock Biotech報告稱，2024年第一季度收入增長了4％，這主要是由其院內業務推動的。
該公司創下了有史以來最低的銷售和營銷費用佔收入的35％。
本季度的毛利率有所提高，但沒有重大更新。
與去年相比，管理費用大幅減少。
宣佈了2024年的預期現金流出量大幅減少，這有望實現舒適的財務狀況。
Business Progress:
業務進展：
Burning Rock is actively shifting its operations from a central lab model to an in-hospital model, which is now a major revenue contributor.
New product deployment and hospital partnerships are expected to drive further growth.
A positive non-GAAP gross profit minus G&A for the whole year of 2024 was predicted.
Their management is focused on increasing sales efficiency, improving gross margin, and reducing both G&A and R&D expenses.
Burning Rock正在積極將其運營從中央實驗室模式轉向院內模式，後者現在是主要的收入來源。
新產品部署和醫院合作伙伴關係預計將推動進一步增長。
預計2024年全年非公認會計准則毛利減去併購將爲正數。
他們的管理層專注於提高銷售效率，提高毛利率，減少併購和研發費用。
More details: Burning Rock Biotech IR
更多詳情： Burning Rock 生物技術投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。